###begin article-title 0
Detection of FLT3 Oncogene Mutations in Acute Myeloid Leukemia Using Conformation Sensitive Gel Electrophoresis
###end article-title 0
###begin p 1
###xml 0 16 0 16 <!--CREATIVE COMMONS-->
CREATIVE COMMONSThis article is an open-access article distributed under the terms and conditions of the Creative Commons Attribution license ().
###end p 1
###begin p 2
###xml 424 431 424 431 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">de novo</italic>
###xml 739 747 <span type="species:ncbi:9606">patients</span>
###xml 1469 1474 <span type="species:ncbi:9606">human</span>
###xml 1515 1523 <span type="species:ncbi:9606">patients</span>
FLT3 (fms-related tyrosine kinase 3) is a receptor tyrosine kinase class III that is expressed on by early hematopoietic progenitor cells and plays an important role in hematopoietic stem cell proliferation, differentiation and survival. FLT3 is also expressed on leukemia blasts in most cases of acute myeloid leukemia (AML). In order to determine the frequency of FLT3 oncogene mutations, we analyzed genomic DNA of adult de novo acute myeloid leukemia (AML). Polymerase chain reaction (PCR) and conformation-sensitive gel electrophoresis (CSGE) were used for FLT3 exons 11, 14, and 15, followed by direct DNA sequencing. Two different types of functionally important FLT 3 mutations have been identified. Those mutations were unique to patients with inv(16), t(15:17) or t(8;21) and comprised fifteen cases with internal tandem duplication (ITD) mutation in the juxtamembrane domain and eleven cases with point mutation (exon 20, Asp835Tyr). The high frequency of the flt3 proto-oncogene mutations in acute myeloid leukemia AML suggests a key role for the receptor function. The association of FLT3 mutations with chromosomal abnormalities invites speculation as to the link between these two changes in the pathogenesis of acute myeloid leukemiaAML. Furthermore, CSGE method has shown to be a rapid and sensitive screening method for detection of nucleotide alteration in FLT3 gene. Finally, this study reports, for the first time in Saudi Arabia, mutations in the human FLT3 gene in acute myeloid leukemia AML patients.
###end p 2
###begin title 3
1. Introduction
###end title 3
###begin p 4
###xml 189 190 189 190 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b1-ijms-9-2194">1</xref>
###xml 191 192 191 192 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b3-ijms-9-2194">3</xref>
###xml 553 554 553 554 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b4-ijms-9-2194">4</xref>
###xml 695 696 695 696 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b5-ijms-9-2194">5</xref>
###xml 945 946 945 946 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b3-ijms-9-2194">3</xref>
###xml 948 949 948 949 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b6-ijms-9-2194">6</xref>
###xml 950 951 950 951 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b8-ijms-9-2194">8</xref>
###xml 1208 1216 1208 1216 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
###xml 1236 1243 1236 1243 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
###xml 1245 1246 1245 1246 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b9-ijms-9-2194">9</xref>
###xml 1248 1250 1248 1250 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b10-ijms-9-2194">10</xref>
###xml 1379 1381 1379 1381 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b11-ijms-9-2194">11</xref>
###xml 905 910 <span type="species:ncbi:9606">human</span>
###xml 1307 1313 <span type="species:ncbi:10090">murine</span>
###xml 1518 1524 <span type="species:ncbi:9606">humans</span>
The FLT3 gene (fms-like tyrosine kinase), is a member of the class III tyrosine kinase receptor family that includes c-kit, c-fms and the platelet-derived growth factor receptors (PDGFRs) [1-3]. Class III receptor tyrosine kinases (RTKs) share sequence homology and have a similar overall structure, with five immunoglobulin-like repeats in the extracellular domain, a single transmembrane domain (TM), a juxtamembrane domain (JM), two intracellular tyrosine kinase domains (TK1 and TK2) divided by a kinase insert domain (KI), and a C-terminal domain [4]. The genomic locus encoding the FLT3 receptor has recently been shown to comprise 24 rather than the expected 21 exons, ranging 83-562 bp [5]. Data from different sources suggest a pathogenic role of FLT3 in acute myeloid leukemia (AML). Hence functional analysis of FLT3 expression has been documented in many cases of AML, besides of immortalized human myeloid and monocytic cell lines [3, 6-8]. The ITD and activation loop mutations of the receptor have resulted in the constitutive FLT3 kinase activity and FLT3 receptors harboring such mutations when introduced into mammalian cells downstream signaling pathways lead to factor-independent growth in vitro and leukemogenesis in vivo [9, 10]. Thus the production of FLT3 mutant protein in primary murine bone marrow cells induces a lethal myeloproliferative phenotype [11]. It is known that FLT3 is a leukemia oncogene and activating FLT3 mutations are likely to contribute in the development of leukemia in humans.
###end p 4
###begin p 5
###xml 126 128 126 128 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b11-ijms-9-2194">11</xref>
###xml 129 131 129 131 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b14-ijms-9-2194">14</xref>
###xml 227 229 227 229 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b11-ijms-9-2194">11</xref>
###xml 231 233 231 233 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b15-ijms-9-2194">15</xref>
###xml 302 304 302 304 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b16-ijms-9-2194">16</xref>
###xml 305 307 305 307 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b18-ijms-9-2194">18</xref>
###xml 394 396 394 396 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b18-ijms-9-2194">18</xref>
###xml 398 400 398 400 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b19-ijms-9-2194">19</xref>
###xml 169 173 <span type="species:ncbi:10090">mice</span>
###xml 347 355 <span type="species:ncbi:9606">patients</span>
In addition, several small molecule inhibitors have also been implicated in blocking the kinase activity of FLT3 effectively [11-14]. These can prolong the life span of mice harboring leukemia expressing mutant FLT3 receptors [11, 15]. In clinical trials, FLT3 inhibitors reduced FLT3 phosphorylation [16-18], and lowered leukemia blast counts in patients with advanced therapy-refractive AML [18, 19].
###end p 5
###begin p 6
###xml 87 95 <span type="species:ncbi:9606">patients</span>
###xml 352 360 <span type="species:ncbi:9606">patients</span>
Until now, no study has reported the frequency and prevalence of FLT3 mutations in AML patients in the Kingdom of Saudi Arabia. This study was conducted with that objective in mind and was therefore undertaken using polymerase chain reaction-conformation sensitive gel electrophoresis (PCR-CSGE) on DNA extracted from archival bone marrow of Saudi AML patients.
###end p 6
###begin title 7
2. Results and Discussion
###end title 7
###begin title 8
2.1. Detection of the FLT3-ITD mutation
###end title 8
###begin p 9
###xml 377 385 377 385 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="f1-ijms-9-2194">Figure 1</xref>
###xml 858 866 858 866 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="f2-ijms-9-2194">Figure 2</xref>
###xml 122 130 <span type="species:ncbi:9606">patients</span>
###xml 247 255 <span type="species:ncbi:9606">patients</span>
###xml 307 315 <span type="species:ncbi:9606">patients</span>
In order to screen for the FLT3-ITD mutation, exons 14 and 15 of the FLT3 gene were amplified from genomic DNA of 129 AML patients using PCR, followed by conformation sensitive gel electrophoresis (CSGE) analysis. Abnormal CSGE patterns in 15 AML patients were identified in PCR fragments and the remaining patients reported no such patterns. These abnormal patterns, shown in Figure 1, were due to conformational changes occurred in the gel indicating nucleotide alteration (in-frame insertion mutation) within the PCR fragment. When direct DNA sequencing analysis was carried out on all 15 AML cases with abnormal CSGE patterns, ITD mutations were detected in all cases with lengths varying between 24-60 bp. The FLT3-ITD mutations detected included either a part or whole stretch of tyrosine-rich sequence of the FLT3 gene located between codons 589-599 (Figure 2). Furthermore, these mutations were located in-frame of the JM domain of FLT receptor which gave the evidence of tandem duplications, thus confirming the ITD in the samples.
###end p 9
###begin title 10
2.2. Detection of the Asp835Tyr mutation
###end title 10
###begin p 11
###xml 315 323 315 323 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="f3-ijms-9-2194">Figure 3</xref>
###xml 388 396 388 396 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="f4-ijms-9-2194">Figure 4</xref>
###xml 717 724 717 724 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="t1-ijms-9-2194">Table 1</xref>
###xml 529 537 <span type="species:ncbi:9606">patients</span>
###xml 652 660 <span type="species:ncbi:9606">patients</span>
In addition to the FLT3-ITD mutation, the Asp835Tyr mutation is also prevalent in AML cases. To screen our cohort for the presence of this mutation, exon 20 of the FLT3 gene was subjected to PCR-CSGE followed by direct sequencing in all 129 AML cases. Eleven cases of AML (8.5%) exhibited an abnormal CSGE pattern (Figure 3), and sequencing revealed a G to C mutation in codon Asp835Tyr (Figure 4). Six of these were classified as AML M4, four of which demonstrated inv(16). In addition, FLT3 ITD mutations were identified in 15 patients; however, no case possessed both an ITD and Asp835 mutation jointly. The detailed clinical characteristics of AML patients forming the basis of this observation are summarized in Table 1.
###end p 11
###begin title 12
2.3. Analysis of correlation with survival
###end title 12
###begin p 13
###xml 348 356 348 356 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="f5-ijms-9-2194">Figure 5</xref>
###xml 102 110 <span type="species:ncbi:9606">patients</span>
###xml 153 161 <span type="species:ncbi:9606">patients</span>
###xml 304 312 <span type="species:ncbi:9606">patients</span>
Survival analysis was calculated using Kaplan-Meier plot for comparison between Asp835Tyr and ITD AML patients. The survival curves were plotted for AML patients with Asp 835 mutation (n = 11) and ITD mutations (n = 15). The Mantel-Cox test demonstrated that the difference between the two groups of AML patients was not statistically significant (Figure 5).
###end p 13
###begin p 14
###xml 313 319 313 319 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">et al.</italic>
###xml 321 323 321 323 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b20-ijms-9-2194">20</xref>
###xml 952 954 952 954 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b20-ijms-9-2194">20</xref>
###xml 955 957 955 957 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b26-ijms-9-2194">26</xref>
###xml 1118 1120 1118 1120 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b27-ijms-9-2194">27</xref>
###xml 1132 1134 1132 1134 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b28-ijms-9-2194">28</xref>
###xml 1143 1145 1143 1145 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b29-ijms-9-2194">29</xref>
###xml 1158 1160 1158 1160 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b30-ijms-9-2194">30</xref>
###xml 99 107 <span type="species:ncbi:9606">patients</span>
###xml 404 412 <span type="species:ncbi:9606">patients</span>
We undertook in this study the analysis of ITD and Asp 835 mutations of the FLT3 gene in Saudi AML patients in order to better understand the prevalence of these mutations in our cohort of cases. FLT3-ITD mutation is thought to cause the constitutive and ligand-independent activation of the receptor, but Fenski et al. [20] have shown that FLT3 oncogene is constitutively activated in 3/18 cases of AML patients and only 1/3 of those cases exhibited the FLT3-ITD mutation. It was therefore suggested that some other mechanisms are operational for the activation of the receptor, either because of mutations elsewhere in the gene or due to autocrine mechanisms. This prompted us to include in our screen exon 20 and identify mutations involving Asp 835. Previous studies indicated that Asp 835 highly conserved homologues, are probably playing a crucial role in the function of the activating loop of the JM region and kinase domain of class III RTKs [20-26]. The frequency of FLT3-ITD mutation identified in this study is much lower than reported for other ethnic populations which range between 20%-25% in Japanese [27], Chinese [28], Thai [29] or German [30] populations. It is interesting to find that all the detected cases of FLT3-ITD mutations exhibited cytogenetic aberrations, in particular t(15;17), t(8;21) and Inv(16). These chromosomal rearrangements are commonly found in adult AML cases as in our cohort inv(16) is the most common event at 26.3%, followed by the presence of t(15;17) translocation (17.8%). The t(8;21) translocation constituted only 8.5% of the cases in our cohort. The FLT3-ITD mutations were all detected in cases with cytogenetic translocations. Whether this reflects a case of global genomic instability or not is unknown. Screening of a larger cohort of samples may shed some light into the potential association between FLT3-ITD mutations and genomic instability.
###end p 14
###begin p 15
###xml 472 474 472 474 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b31-ijms-9-2194">31</xref>
###xml 589 591 589 591 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b32-ijms-9-2194">32</xref>
###xml 592 594 592 594 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b33-ijms-9-2194">33</xref>
###xml 660 662 660 662 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b34-ijms-9-2194">34</xref>
###xml 676 678 676 678 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b35-ijms-9-2194">35</xref>
###xml 786 788 786 788 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b35-ijms-9-2194">35</xref>
###xml 820 822 820 822 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b34-ijms-9-2194">34</xref>
###xml 579 587 <span type="species:ncbi:9606">patients</span>
###xml 776 784 <span type="species:ncbi:9606">patients</span>
###xml 801 809 <span type="species:ncbi:9606">patients</span>
The first aim of this study was to screen the FLT3 gene for previously reported mutations in AML using a sensitive and simple method to determine the frequency of the mutations. Efficiency and sensitivity were the main criteria to be considered in the selection of the method of mutation detection to be used in the analysis of the FLT3 gene. CSGE was the method of choice for screening the FLT3 gene because of its high sensitivity and simplicity as reviewed by Ganguly [31]. The technique has been used in different studies for the analysis of factor VIII gene in hemophilia A patients [32-33] and other genes including the von Willebrand factor (VWF) gene [34], factor IX [35]. For example, the sensitivity of CSGE in the detection of mutations was 100% in 21 hemophilia B patients [35] and 88% in patients with VWD [34]. Moreover, CSGE was selected as the method of choice to ensure all previously known FLT3 mutations can be detected.
###end p 15
###begin title 16
3. Conclusions
###end title 16
###begin p 17
###xml 42 47 <span type="species:ncbi:9606">human</span>
###xml 83 91 <span type="species:ncbi:9606">patients</span>
In conclusion, we report mutations in the human FLT3 gene in a cohort of Saudi AML patients. These mutations are likely to lead to constitutive activation of the FLT3 receptor. The FLT3-ITD mutation rates reported in this study are lower than expected which would justify that future studies will need to screen the complete coding and regulatory sequence of the FLT3 gene to determine whether additional mutations are associated with the pathogenesis of myeloid malignancy.
###end p 17
###begin title 18
4. Experimental Section
###end title 18
###begin title 19
###xml 5 12 <span type="species:ncbi:9606">Patient</span>
4.1. Patient DNA samples
###end title 19
###begin p 20
###xml 380 386 380 386 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">et al.</italic>
###xml 388 390 388 390 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b36-ijms-9-2194">36</xref>
###xml 708 710 708 710 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b37-ijms-9-2194">37</xref>
###xml 920 922 920 922 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b38-ijms-9-2194">38</xref>
###xml 597 602 <span type="species:ncbi:9606">women</span>
###xml 607 610 <span type="species:ncbi:9606">men</span>
###xml 814 822 <span type="species:ncbi:9606">patients</span>
Sample DNA was collected from 129 routinely-processed unstained bone marrow slides diagnosed as Acute myeloid leukemia (AML), which had been stored in a box at room temperature in an air-conditioned storage room for up to 20 years (from 1987 to 2007) in the archives of Hematology Laboratory at King Abdulaziz University Hospital. Genomic DNA was extracted (as optimized by Gari, et al. [36]) from the scraped material of each bone marrow slide using the Nucleon BACC1 DNA extraction kit (Nucleon Biosciences). Theses samples of genomic DNA were selected at presentation from 129 cases of AML (53 women, 76 men, and mean age 40.3 years, range 22-65). The cases were classified according to the FAB criteria [37] as M0 (n = 5), M1 (16), M2 (n = 38), M3 (n = 23), M4 (n = 34), M5 (n = 9) and M6 (n = 4). Sixty-eight patients had good risk and 61 had intermediate risk disease, as defined by standard cytogenetic analysis [38]; inv(16) (n = 34), t(15;17) (n = 23) and t(8;21) (n = 11).
###end p 20
###begin title 21
4.2. Genomic DNA amplification
###end title 21
###begin p 22
###xml 371 378 371 378 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="t2-ijms-9-2194">Table 2</xref>
DNA amplification was performed by polymerase chain reaction (PCR). All exons, and intron/exon boundaries of the FLT3 gene involved in this study were amplified independently. The entire coding sequence and intron/exon boundaries corresponding to exons 14, 15 (ITD) and 20 (Asp835) of the FLT3 gene were amplified independently, using oligonucleotide primers as shown in Table 2.
###end p 22
###begin p 23
###xml 68 69 68 69 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">4</sub>
###xml 70 71 70 71 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 73 74 73 74 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">4</sub>
###xml 222 223 217 218 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 331 338 325 326 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#176;</sup>
###xml 421 428 409 410 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#176;</sup>
###xml 459 466 441 442 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#176;</sup>
###xml 502 509 478 479 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#176;</sup>
###xml 142 148 <span type="species:ncbi:9913">bovine</span>
The PCR reactions contained the following: genomic DNA (500 ng), (NH4)2SO4 (16.6 mM), Tris HCL (pH 8.0, 67 mM), beta-mercaptoethanol (10 mM), bovine serum albumin (BSA, 100 mug), each primer (300 ng), dNTPs (200 muM), MgCl2 (1.50 mM), and Taq DNA polymerase (1 U) in a final volume of 50 muL. Samples were initially denatured at 94degreesC for 5 minutes. DNA amplification was performed by 35 cycles of denaturation at 94degreesC for 1 minute, annealing at 55degreesC for 30 second and extension at 72 degreesC for 30 second. Five muL of each PCR products was loaded onto 5% polyacrylamide gel or agarose gel to ensure the amplification had occurred.
###end p 23
###begin title 24
4.3. Mutation detection
###end title 24
###begin p 25
###xml 100 102 100 102 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b31-ijms-9-2194">31</xref>
###xml 158 165 158 159 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#176;</sup>
###xml 205 212 199 200 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#176;</sup>
Conformation sensitive gel electrophoresis (CSGE) was used to screen for mutations as described in [31]. Briefly, PCR products were denatured by heating to 95degreesC for 5 minutes and then incubated at 65degreesC for 30 minutes. These PCR products were resolved on 10% polyacrylamide gels; 99:1 ratio acrylamide (BDH):bis-acrolypiperazine (BAP; Fluka), 10% ethylene glycol (Sigma), 15% formamide (Sigma) and 0.5 x TTE buffer (1 x TTE = 89 mM Tris, 28.5 mM taurine, 0.2 mM EDTA). Samples displaying abnormal CSGE profiles compared to that obtained from a normal individual were directly sequenced using automated DNA sequencer (API 310 prizm).
###end p 25
###begin p 26
The authors are grateful to Mr. A. Abdulbaqi at hematology laboratory for providing archival bone marrow slides of AML cases. This project is supported by a grant from Deanship of Scientific Research, King Abdulaziz University, Saudi Arabia.
###end p 26
###begin title 27
References
###end title 27
###begin article-title 28
Signal transduction by receptors with tyrosine kinase activity
###end article-title 28
###begin article-title 29
A receptor tyrosine kinase specific to hematopoietic stem and progenitor cell-enriched populations
###end article-title 29
###begin article-title 30
###xml 0 5 <span type="species:ncbi:9606">Human</span>
Human FLT3/FLK2 gene: cDNA cloning and expression in hematopoietic cells
###end article-title 30
###begin article-title 31
Growth factor receptor tyrosine kinase
###end article-title 31
###begin article-title 32
Identification of novel FLT-3 Asp835 mutations in adult acute myeloid leukaemia
###end article-title 32
###begin article-title 33
###xml 44 49 <span type="species:ncbi:9606">human</span>
Expression of the FMS/KIT-like gene FLT3 in human acute leukemias of the myeloid and lymphoid lineages
###end article-title 33
###begin article-title 34
###xml 48 53 <span type="species:ncbi:9606">human</span>
Expression of FLT3 receptor and FLT-3 ligand in human leukemia-lymphoma cell lines
###end article-title 34
###begin article-title 35
Expression of FLT3 receptor and response of to FLT3 ligand by leukemic cells
###end article-title 35
###begin article-title 36
Signaling through the hematopoietic cytokine receptors
###end article-title 36
###begin article-title 37
###xml 58 63 <span type="species:ncbi:10090">mouse</span>
PML/RARalpha and FLT3-ITD induce an APL-like disease in a mouse model
###end article-title 37
###begin article-title 38
###xml 59 64 <span type="species:ncbi:9606">human</span>
###xml 128 134 <span type="species:ncbi:10090">murine</span>
FLT3 internal tandem duplication mutations associated with human acute myeloid leukemias induce myeloproliferative disease in a murine bone marrow transplant model
###end article-title 38
###begin article-title 39
###xml 0 7 0 7 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">In vivo</italic>
###xml 45 51 <span type="species:ncbi:10090">murine</span>
In vivo treatment of mutant FLT3-transformed murine leukemia with a tyrosine kinase inhibitor
###end article-title 39
###begin article-title 40
Inhibition of FLT3-mediated transformation by use of a tyrosine kinase inhibitor
###end article-title 40
###begin article-title 41
A FLT3 tyrosine kinase inhibitor is selectively cytotoxic to acute myeloid leukemia blasts harboring FLT3 internal tandem duplication mutations
###end article-title 41
###begin article-title 42
Inhibition of mutant FLT3 receptors in leukemia cells by the small molecule tyrosine kinase inhibitor PKC412
###end article-title 42
###begin article-title 43
###xml 122 130 <span type="species:ncbi:9606">patients</span>
An innovative phase I clinical study demonstrates inhibition of FLT3 phosphorylation by SU11248 in acute myeloid leukemia patients
###end article-title 43
###begin article-title 44
###xml 38 46 <span type="species:ncbi:9606">patients</span>
A phase 2 clinical study of SU5416 in patients with refractory acute myeloid leukemia
###end article-title 44
###begin article-title 45
###xml 79 87 <span type="species:ncbi:9606">patients</span>
Phase 1 clinical results with tandutinib (MLN518), a novel FLT3 antagonist, in patients with acute myelogenous leukemia or high-risk myelodysplastic syndrome: Safety, pharmacokinetics, and pharmacodynamics
###end article-title 45
###begin article-title 46
PKC 412 FLT3 inhibitor therapy in AML: Results of a phase II trial
###end article-title 46
###begin article-title 47
Constitutive activation of FLT3 in acute myeloid leukaemia and its consequences for growth of 32D cells
###end article-title 47
###begin article-title 48
Internal tandem duplication of the FLT3 gene is a novel modality of elongation mutation which causes constitutive activation of the product
###end article-title 48
###begin article-title 49
###xml 66 71 <span type="species:ncbi:9606">human</span>
Activating mutation of D835 within the activation loop of FLT3 in human hematologic malignancies
###end article-title 49
###begin article-title 50
###xml 194 202 <span type="species:ncbi:9606">children</span>
Tandem duplication of the FLT3 gene is found in acute lymphoblastic leukaemia as well as acute myeloid leukaemia but not in myelodysplastic syndrome or juvenile chronic myelogenous leukaemia in children
###end article-title 50
###begin article-title 51
FLT3 internal tandem duplication mutations in adult acute myeloid leukaemia define a high-risk group
###end article-title 51
###begin article-title 52
Tandem duplications of the FLT3 receptor gene are associated with leukemic transformation of myelodysplasia
###end article-title 52
###begin article-title 53
Prognostic implication of FLT3 and N-RAS gene mutations in acute myeloid leukemia
###end article-title 53
###begin article-title 54
###xml 194 202 <span type="species:ncbi:9606">patients</span>
Internal tandem duplication of the FLT3 gene is preferentially seen in acute myeloid leukemia and myelodysplastic syndrome among various hematological malignancies. A study on a large series of patients and cell lines
###end article-title 54
###begin article-title 55
###xml 90 98 <span type="species:ncbi:9606">patients</span>
Analysis of FLT3 internal tandem duplication and D835 mutations in Chinese acute leukemia patients
###end article-title 55
###begin article-title 56
Mutations of the FLT3 gene in adult acute myeloid leukemia: determination of incidence and identification of a novel mutation in a Thai population
###end article-title 56
###begin article-title 57
###xml 45 53 <span type="species:ncbi:9606">patients</span>
Analysis of FLT3 activating mutations in 979 patients with acute myelogenous leukemia: association with FAB subtypes and identification of subgroups with poor prognosis
###end article-title 57
###begin article-title 58
An update on conformation sensitive gel electrophoresis
###end article-title 58
###begin article-title 59
Precise carrier diagnosis in families with haemophilia A: Use of conformational sensitive gel electrophoresis for mutation screening and polymorphism analysis
###end article-title 59
###begin article-title 60
###xml 109 117 <span type="species:ncbi:9606">patients</span>
Relationship between factor VIII mutation type and inhibitor development in a cohort of previously untreated patients treated with recombinant factor VIII (Recombinate). Recombinate PUP Study Group
###end article-title 60
###begin article-title 61
MCMDM-1VWD Study Group. Mutational analysis of the von Willebrand factor gene in type 1 von Willebrand disease using conformation sensitive gel electrophoresis: a comparison of fluorescent and manual techniques
###end article-title 61
###begin article-title 62
Rapid method for haemophilia B mutation detection using conformation sensitive gel electrophoresis
###end article-title 62
###begin article-title 63
Pilot study of DNA extraction from archival unstained bone marrow slides: comparison of three rapid methods
###end article-title 63
###begin article-title 64
Proposal for the classification of the acute leukaemias. French American British (FAB) cooperative group
###end article-title 64
###begin article-title 65
###xml 79 87 <span type="species:ncbi:9606">patients</span>
###xml 162 170 <span type="species:ncbi:9606">Children</span>
The importance of diagnostic cytogenetics on outcome in AML: Analysis of 1,612 patients entered into the MRC AML 10 trial. The Medical research Council Adult and Children's Leukaemia Working Parties
###end article-title 65
###begin p 66
###xml 64 72 <span type="species:ncbi:9606">patients</span>
CSGE analysis of exons 14 and 15 PCR product amplified from AML patients. CSGE gel demonstrating abnormal patterns (indicated by arrowheads) compared to normal pattern (lane N, PCR product amplified from healthy individual, indicated by arrow).
###end p 66
###begin p 67
Sequence analysis of exons 14 and 15 of FLT3 gene. Inserted nucleotides for tandem duplications of the Flt3 gene observed in AML cases with apparent CSGE patterns.
###end p 67
###begin p 68
CSGE analysis of exon 20 of FLT3 gene demonstrating abnormal CSGE pattern compared to that seen in a normal individual (Lane N).
###end p 68
###begin p 69
Point mutation in exon 20 of FLT 3 gene in AML cases detected by direct DNA sequence analysis. Mutated nucleotides are represented by changed amino acid, (bold).
###end p 69
###begin p 70
###xml 356 357 356 357 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 50 58 <span type="species:ncbi:9606">patients</span>
###xml 98 106 <span type="species:ncbi:9606">patients</span>
###xml 146 154 <span type="species:ncbi:9606">patients</span>
###xml 197 205 <span type="species:ncbi:9606">patients</span>
###xml 240 248 <span type="species:ncbi:9606">patients</span>
Kaplan-Meier cumulative survival analysis for AML patients with Asp 835 and ITD mutations and AML patients without mutations. Blue line indicates patients with Asp 835 mutation, red line indicates patients with ITD mutations and green line patients without flt3 mutations. The survival analysis showed no significance differences between the three groups (p = 0.15).
###end p 70
###begin p 71
Clinical characteristics of AML cases and accompanied mutations.
###end p 71
###begin p 72
Oligonucleotide primers used in PCR analysis.
###end p 72
###begin p 73
F: forward; R: reverse.
###end p 73

